Replies to post #19929 on Synaptogenix Inc (SNPX)

[runncoach]

Haven't had a chance to look at this particular one. Just passing along. My understanding is there are multiple tests and used in combination is incredibly accurate. The PKCe part of the testing I believe has already been confirmed. I've read through all the patents including the specific graphs and charts they used including specific PKCe levels and the like. You could be right on this particular PR. I'll have to look.

That said, I'm not the huge "biomarker" fan that some are. It's why I didn't buy SAVA at 2 bucks but waited until the 8s and missed the first 4 bags lol. Each different MOA will likely have its own set of biomarkers (likely a reason AVXL PR was a dud yesterday). SNPX happens to be PKCe but just because brain autopsies and such show low PKCe levels doesn't necessarily mean we'll be the key to solving AD. The way I like to see the biomarkers used it to see how much and for how long bryostatin can elevate and normalize PKCe levels without causing downregulation. That's more important to me at this stage.

[runncoach]

First time I've seen the diagnostic company website's new update. Pretty informative and they've come a long way. They've brought in at least 10 million dollars in private investment lately as well. Yes there are 3 different tests used. All 3 show different "windows" into synaptic health. The one presented at AAIC is almost full proof accurate based on the autopsy results and a different look into the synaptic window from PKCe levels. The PKCe assay is Sensitivity: 100%, Specificity 96% per autopsy research and the 3rd test similar as well. What the PKCe essay can be used for as well is distinguishing the stage of AD, the pace of decline, etc. I can probably go back and find the specific research for the patents if I have the time.

Some asked if this is confirmative of our MOA? I mean it is our MOA and we know PKCe levels (and dozens of other biometric metric levels) can be lower in AD patients. Can you imagine a test that can diagnose and measure AD levels based on a measurement (PKCe) so impacted by bryostatin? It's either big, or it's not. I guess we'll have to wait a few months to know for sure.